fbpx
Sunday, May 22, 2022
More

    Lupin benefits from the USFDA’s approval to commercialise Sevelamer Carbonate.

    Lupin NSE 2.08 percent stock jumped 1.6 percent in early trade on Monday after the pharmaceutical announced that it had got approval from the US Food and Drug Administration to market Sevelamer Carbonate for oral suspension. It is used to measure serum phosphorus in people who are on dialysis for chronic kidney disease (CKD).
    On the NSE, the pharmaceutical major’s stock surged to a high of Rs 912, up from a previous closing of Rs 897.75.


    The US Food and Drug Administration (FDA) has approved Lupin’s abbreviated new drug application (ANDA) Sevelamer Carbonate for oral suspension in the American market, the company said in a statement. The product will be produced in the company’s Goa plant.
    According to IQVIA MAT September statistics, Sevelamer Carbonate for Oral Suspension has anticipated yearly sales of $51.7 million in the United States, according to news agency PTI.
    The latest USFDA approval follows a similar nod from the US Department of Health and Human Services for blood pressure medicine.


    On Friday, the business said that it has acquired tentative approval from the US Food and Drug Administration for its generic Azilsartan Medoxomil pills, which are used to treat high blood pressure.
    According to Lupin, the USFDA has tentatively approved the abbreviated new drug application (ANDA) Azilsartan Medoxomil tablets in doses of 40 mg and 80 mg.


    As per the sources, these are generic versions of Arbor Pharmaceuticals’ Edarbi tablets, 40 mg and 80 mg, LW, Lupin said, adding that the medication would be manufactured in Nagpur.

    Latest Posts

    Don't Miss

    Latest Posts

    Stay in touch

    To be updated with all the latest news, offers and special announcements.